Aquestive Therapeutics (AQST) has issued an update.
Aquestive Therapeutics has announced encouraging preliminary results from their study on Anaphylm™, a groundbreaking non-invasive epinephrine treatment for severe allergic reactions that could be the first of its kind if approved by the FDA. The study showed no significant difference in epinephrine absorption between self-administered and healthcare provider-administered Anaphylm, matching the rapid 15-minute median time to peak concentration. This innovative treatment could offer a life-saving alternative for allergy sufferers, with plans for a full product launch by early 2026, pending completion of ongoing clinical studies and regulatory approval.
See more insights into AQST stock on TipRanks’ Stock Analysis page.
